Study of inetetamab for first-line HER2-positive metastatic breast cancer

This Phase 3 trial tests whether a new HER2-targeting drug (inetetamab) combined with rapamycin and standard chemotherapy works better than the control approach for HER2-positive metastatic breast cancer. It is mainly for people whose tumor genetics suggest a specific “PAM pathway” problem.

This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.

This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.

This trial tests a combination of three drugs (a targeted therapy called chidamide, an immunotherapy called a PD-1 inhibitor, and a drug called anlotinib that blocks blood vessel growth) for people with HER2-low, hormone receptor-positive breast cancer that has spread to other parts of the body or cannot be removed with surgery. It is for those whose cancer has stopped responding to hormone therapy and who have had little or no prior chemotherapy.

This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.

This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.